Nutraplus India Peer Comparison

BSE: 524764

₹2.10

₹0.10 (5.00%)

As on 13-Dec-2021IST

Market cap

₹7 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

--

Div. Yield

0 %

Edit

	Nutraplus India	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	7	35,497	29,798	16,589	15,507
Revenue (₹ Cr)	--	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	-0.32	1,018.97	497.77	603.02	270.18
Net Margin (%)	-167.37	10.47	20.72	22.63	23.29
RoE (%)	--	21.30	28.49	19.61	14.45
Price to Earnings	--	35.10	59.86	27.51	56.31
Price-To-Book	--	6.79	14.74	4.76	7.48

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Nutraplus India	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	--	7,896.00	1,476.84	2,386.88	1,200.09
Total Income	0.00	7,968.78	1,497.35	2,421.45	1,244.53
Total Expenditure	0.05	6,427.14	1,153.58	1,704.30	693.24
EBITDA	-0.05	1,468.85	323.26	682.58	506.84
Depreciation	--	384.13	65.55	60.61	54.37
EBIT	-0.05	1,084.73	257.71	621.98	452.47
Interest	0.00	175.78	8.30	2.41	1.04
Other Income	0.00	72.79	20.51	34.57	44.45
Exceptional Items	--	-10.38	76.40	--	--
Profit before Tax	-0.05	971.35	346.33	654.13	494.55
Provision for Tax	--	263.88	86.22	168.50	122.91
Profit after Tax	-0.05	707.47	260.11	485.63	371.64

Liabilities (₹ Cr)

	Nutraplus India	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	-5.35	4,446.19	1,524.81	2,817.37	1,812.72
Minority Interest	--	195.37	--	--	--
Non-Current Liabilities	1.79	811.91	189.39	466.05	37.47
Current Liabilities	8.73	2,668.27	465.69	470.16	184.06
Total Liabilities	5.16	8,121.73	2,179.88	3,753.59	2,034.25

Assets (₹ Cr)

	Nutraplus India	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	0.00	3,565.87	1,040.38	1,418.43	899.01
Current Assets	5.16	4,555.86	1,139.50	2,335.16	1,135.24
Total Assets	5.16	8,121.73	2,179.88	3,753.59	2,034.25
Total Debt*	1.79	731.70	136.01	0.00	0.38
Net Current Assets	-3.56	1,887.59	673.81	1,865.00	951.18
Contingent Liabilities	--	393.94	8.97	4.82	3.91

Cashflow (₹ Cr)

	Nutraplus India	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	0.00	851.71	317.40	391.52	244.52
Cash Flow from Investing Activities	--	-94.00	-298.16	-615.65	-159.99
Cash from Financing Activities	0.00	-813.96	24.96	-6.23	-98.77
Net Cash Inflow / Outflow	0.00	-56.25	44.21	-230.35	-14.24

Ratios

Profitability Ratios

	Nutraplus India	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	0.00	22.49	23.45	25.50	29.62
ROE (%)	0.00	19.19	18.54	18.94	22.26
ROA (%)	-0.96	8.94	12.97	13.34	19.90
EBIT Margin (%)	--	19.52	23.28	30.05	45.94
Net Margin (%)	-6,158.86	8.88	17.37	20.06	29.86
Cash Profit Margin (%)	--	13.61	22.05	22.79	35.50

Growth Ratios

	Nutraplus India	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	--	18.59	-5.24	4.54	18.01
EBIT Growth (%)	18.37	19.81	-27.65	4.50	18.31
Net Profit Growth (%)	18.65	34.10	-13.32	3.13	20.62
EPS Growth (%)	18.78	30.75	-13.32	3.12	20.62
Book Value Growth (%)	-0.95	50.94	18.89	20.94	18.74

Valuation Ratios

	Nutraplus India	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	0.00	29.84	59.57	27.24	47.19
Price / Book Value	0.00	4.58	10.17	4.71	9.67
Dividend Yield (%)	--	0.28	0.10	0.46	0.64
EV/EBITDA	-377.41	13.55	44.72	18.35	31.81
Market Cap (₹ Cr)	--	20,327.45	15,494.53	13,228.83	17,537.35

Solvency Ratios

	Nutraplus India	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	-0.33	0.17	0.09	0.00	0.00
Short term debt to equity ratio	--	0.11	--	--	0.00
Current Ratio	0.59	1.71	2.45	4.97	6.17
Quick Ratio	0.59	0.98	1.62	3.53	4.87
Interest Coverage	-130.45	6.53	42.74	271.97	475.76

Operating Efficiency Ratios

	Nutraplus India	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	--	25.36	21.38	40.63	43.47
Asset Turnover	0.00	1.01	0.74	0.66	0.64
Receivable days	--	87.83	85.17	132.12	132.49
Inventory Days	--	78.64	90.97	102.08	68.07
Payable days	--	174.97	137.94	133.54	123.94
Cash Conversion Cycle	--	-8.50	38.21	100.66	76.63

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.